Surpassing approximately ten trillion yuan ($1.4 trillion) in 2021, the Chinese Healthcare market ranks as the second largest in the world. The recent growth in this market is driven by a rapid expansion of the share of the public covered by basic medical insurance as well as an increase in the types of technologies that are covered. Beyond simply an emerging as a dominant consumer of healthcare technology, China is rapidly becoming a source of innovation in biopharmaceuticals, medical devices, and digital health. What was once a market or either 'me-too' or at times 'me -worse' technology has evolved into a supplier of cutting-edge medical solutions. Some of these solutions are targeted at specific nuances of the Chinese market while others will generate value globally. It is now clear that any healthcare decision maker over the next several decades will need to have an understanding of this market and its role in the global healthcare ecosystem. It is also clear that success in the Chinese market will not be achieved by simply applying modified versions of global strategies. The sheer scope of the market combined with the complexity of healthcare and an active government interested in domestic production requires careful consideration of the sources of value creation and capture in this market. In addition, managers in domestic Chinese firms need to more broadly understand the needs of other global healthcare markets and how their technologies can be used to create and capture global value. Absent that understanding, domestic firms are unlikely to be able to optimally structure the investments and partnerships with global firms. Kellogg's 'Deep Dive: Chinese Healthcare Market' combines in class case and lecture-based learning, leading practitioner guest lectures, a breadth of networking opportunities, and cultural immersion opportunities designed to prepare future business decisionmakers in healthcare to interact with the Chinese market.